|
|
Article: GSK's Requip significantly improves restless legs syndrome.(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- June 14, 2004
CopyrightCOPYRIGHT 2004 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Over a third of patients taking GlaxoSmithKline's Requip (ropinirole HCl) for restless legs syndrome in clinical trials experienced significant improvement in their symptoms at one week, according to clinical trial results presented at the Associated Professional Sleep Societies' annual meeting in Philadelphia, USA. The results were from combined data from three double-blind, placebo-controlled trials of Requip in RLS, which included 618 patients aged 18-79 years.
Requip is under review by the US Food and Drug Administration for the treatment of RLS, for which there is no currently-approved therapy in the USA.
"The results show that over one-third of ...